It was recently demonstrated that the treatment of mice bearing BC patient-derived xenografts (PDXs) with a humanized anti-receptor tyrosine-kinase-like orphan receptor 1 (ROR1) monoclonal antibody repressed the expression of BCSCs genes, reduced the activation of Rho-GTPases, YAP/TAZ, and BMI1, and impaired the capacity of BC PDXs to metastasize [24]. The gene discussed is ROR1; the disease is breast cancer.